, Volume 12, Issue 3, pp 392–414 | Cite as

(Re)configuring research value: international commercial clinical trials in the Russian Federation

  • Olga ZvonarevaEmail author
  • Nora Engel
  • Natalia Kutishenko
  • Klasien Horstman
Original Article


Clinical trials of new drugs are generally understood in terms of contribution to the future well-being of patients and society at large, while studies of the political economy of trials reveal that global health inequalities have come to sustain the continuous and lucrative operation of this enterprise. The divide between profit generation and improvements in local well-being could be especially vivid when international commercial clinical trials are conducted in new, non-traditional locations outside of North America and Western Europe. This article focuses on how this divide is managed in the everyday work of conducting trials in a research centre in Russia. It explores how investigators and research participants engage in the work of translating trials into academic capacity-building, development of local medical expertise and provision of public health benefits. That is, research value is being multiply configured in clinical, scientific and economic domains. We view the conduct of clinical trials as a boundary process which, through enabling multiplication of value, bridges the realms of health and wealth. This reading of the process of conducting trials opens up opportunities to think about ways to maximise the value of medical experimentation and to (re)link clinical research and public good.


clinical trials Russia health inequalities boundary process cardiovascular disease 



This article benefited from perspectives of many physicians-investigators and clinical research experts in Russia. Authors are especially grateful to Dr Grant Shekhyan and Svetlana Zavidova. The authors appreciate careful proofreading of the text by Jean Kollantai.

Authors declare no conflict of interest.


  1. ACTO (Association of Clinical Trials Organisations) (2015) ACTO Newsletter #10: Summary of 2014 results. Moscow., accessed 30 September 2015.
  2. Anderson, J.A. (2010) Clinical research in context: Reexamining the distinction between research and practice. The Journal of medicine and philosophy 35(1): 46–63.CrossRefGoogle Scholar
  3. Anokina, A. and Meshkov, D. (2007) Going further east in CEE. International Clinical Trials (Summer): 24–29.Google Scholar
  4. Appelbaum, P.S. (2010) Clarifying the ethics of clinical research: A path toward avoiding the therapeutic misconception. American Journal of Bioethics 2(2): 22–23.CrossRefGoogle Scholar
  5. Appelbaum, P.S., Lidz, C.W. and Grisso, T. (2004) Therapeutic misconception in clinical research: Frequency and risk factors. IRB 26(2): 1–8.CrossRefGoogle Scholar
  6. Babayan, E.A. and Ytkin, O.B. (1982) General principles of assessment of medicines in USSR and other countries/Бабаян Э.А. и Уткин О.Б. (1982) Основные положения апробации лекарственных средств в СССР и зарубежных странах. М: Медицина.Google Scholar
  7. Balázs, K., Faulkner, W. and Schimank, U. (1995) Transformation of the research systems of post-communist central and eastern Europe: An introduction. Social Studies of Science 25(4): 613–632.CrossRefGoogle Scholar
  8. Belmont Report (1979) The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research,
  9. Benatar, S.R. (2004) Towards progress in resolving dilemmas in international research ethics. The Journal of Law, Medicine & Ethics 32(4): 574–582.CrossRefGoogle Scholar
  10. Benatar, S.R. and Fleisher, T.E. (2007) Ethical issues in research in low-income countries. International Journal of Tuberculosis & Lung Disease 11(6): 617–623.Google Scholar
  11. Brown, J.V. and Rusinova, N.L. (1997) Russian medical care in the 1990s: A user’s perspective. Social Science & Medicine 45(8): 1265–1276.CrossRefGoogle Scholar
  12. Clarke, A.E. and Star, S.L. (2008) The social worlds framework: A theory/methods package. In: E.J. Hackett, O. Amsterdamska, M. Lynch and J. Wajcman (eds.) The Handbook of Science and Technology Studies. Cambridge, MA: MIT Press, pp. 113–139.Google Scholar
  13. Cooper, M. (2008) Experimental labour – offshoring clinical trials to China. East Asian Science, Technology and Society: An International Journal 2(1): 73–92.Google Scholar
  14. de Melo-Martín, I. and Ho, A. (2008) Beyond informed consent: The therapeutic misconception and trust. Journal of medical ethics 34(3): 202–205.CrossRefGoogle Scholar
  15. de Vries, M.C. et al (2011) Ethical issues at the interface of clinical care and research practice in pediatric oncology: A narrative review of parents’ and physicians' experiences. BMC medical ethics 12(18),
  16. Dumit, J. (2012) Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham: Duke University Press.CrossRefGoogle Scholar
  17. Easter, M.M., Henderson, G.E., Davis, A.M., Churchill, L.R. and King, N.M.P. (2006) The many meanings of care in clinical research. Sociology of Health & Illness 28(6): 695–712.CrossRefGoogle Scholar
  18. Emanuel, E.J., Wendler, D., Killen, J. and Grady, C. (2004) What makes clinical research in developing countries ethical? The benchmarks of ethical research. The Journal of infectious diseases 189(5): 930–937.CrossRefGoogle Scholar
  19. Epstein, S. (1996) Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley, CA: University of California Press.Google Scholar
  20. Fairhead, J., Leach, M. and Small, M. (2006) Public engagement with science? Local understandings of a vaccine trial in the Gambia. Journal of biosocial science 38(1): 103–116.CrossRefGoogle Scholar
  21. Fisher, J.A. (2009) Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press.Google Scholar
  22. Fisher, J.A. (2015) “Ready-to-recruit” or “ready-to-consent” populations? Informed consent and the limits of subject autonomy. In: S. Sismondo and J.A. Green (eds.) The Pharmaceutical Studies Reader. Wiley-Blackwell, pp. 195–207.Google Scholar
  23. Fujimura, J.H. (1992) Crafting science: Standardized packages, boundary objects, and “translation”. In: A. Pickering (ed.) Science as Practice and Culture. Chicago, IL: University of Chicago Press, pp. 168–211.Google Scholar
  24. Gabe, J., Williams, S., Martin, P. and Coveney, C. (2015) Intoruction: Pharmaceuticals and society: Power, promises and prospects. Social Science & Medicine 131: 193–198.CrossRefGoogle Scholar
  25. Gaponenko, N. (1995) Transformation of the research system in a transitional society: The case of Russia. Social Studies of Science 25(4): 685–703.CrossRefGoogle Scholar
  26. Geissler, P.W. and Pool, R. (2006) Editorial: Popular concerns about medical research projects in sub-Saharan Africa – a critical voice in debates about medical research ethics. Tropical Medicine & International Health 11(7): 975–982.CrossRefGoogle Scholar
  27. Geissler, P.W., Kelly, A., Imoukhuede, B. and Pool, R. (2008) “He is now like a brother, I can even give him some blood” – relational ethics and material exchanges in a malaria vaccine “trial community” in The Gambia. Social science & medicine 67(5): 696–707.CrossRefGoogle Scholar
  28. Gikonyo, C., Bejon, P., Marsh, V. and Molyneux, S. (2008) Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast. Social Science & Medicine 67(5): 708–720.CrossRefGoogle Scholar
  29. Hallowell, N., Cooke, S., Crawford, G., Lucassen, A. and Parker, M. (2009) Distinguishing research from clinical care in cancer genetics: Theoretical justifications and practical strategies. Social science & medicine 68(11): 2010–2017.CrossRefGoogle Scholar
  30. Heaven, B. (2010) Bridging the ontological divide: Different social worlds in the conduct of a pilot study. In: T. Moreira and C. Will (eds.) Medical Proofs, Social Experiments: Clinical Trials in Shifting Contexts. Farnham: Ashgate Publishing, pp. 39–47.Google Scholar
  31. Jespersen, A.P., Bønnelycke, J. and Eriksen, H.H. (2014) Careful science? Bodywork and care practices in randomised clinical trials. Sociology of Health & Illness 36(5): 655–669.CrossRefGoogle Scholar
  32. Kelly, A.H., Ameh, D., Majambere, S., Lindsay, S. and Pinder, M. (2010) “Like sugar and honey”: The embedded ethics of a larval control project in The Gambia. Social science & medicine 70(12): 1912–1919.CrossRefGoogle Scholar
  33. Kelly, A.H. and Geissler, P.W. (eds.) (2012) Investigating the ethics and economics of medical experimentation. In: The Value of Transnational Medical Research: Labour, Participation and Care. London: Routledge, pp. 1–12.Google Scholar
  34. Kimmelman, J. (2007) The therapeutic misconception at 25: Treatment, research and confusion. Hastings Center Report 37(7): 36–42.CrossRefGoogle Scholar
  35. Lairumbi, G.M. et al (2008) Promoting the social value of research in Kenya: Examining the practical aspects of collaborative partnerships using an ethical framework. Social science & medicine 67(5): 734–747.CrossRefGoogle Scholar
  36. Lakoff, A. (2004) The anxieties of globalization: Antidepressant sales and economic crisis in Argentina. Social Studies Of Science 32(2): 247–269.CrossRefGoogle Scholar
  37. Law, J. (2006) Big Pharma: How the World’s Biggest Drug Companies Control Illness. London: Constable & Robinson Ltd.Google Scholar
  38. Markina, N. (2013) In case electronic registration does not work, complain to the Ministry of Health/Маркина, Н. (2013) Если не работает электронная запись, жалуйтесь в Минздрав. Газета.ru.
  39. Marsh, V., Kamuya, D., Rowa, Y., Gikonyo, C. and Molyneux, S. (2008) Beginning community engagement at a busy biomedical research programme: Experiences from the KEMRI CGMRC-wellcome trust research programme, Kilifi, Kenya. Social Science & Medicine 67(5): 721–733.CrossRefGoogle Scholar
  40. Miller, F.G. (2004) Research ethics and misguided moral intuition. Journal of Law, Medicine and Ethics 32(1): 111–116.CrossRefGoogle Scholar
  41. Molyneux, S. and Geissler, P.W. (2008) Ethics and the ethnography of medical research in Africa. Social Science & Medicine 67(5): 685–695.CrossRefGoogle Scholar
  42. Morreim, E.H. (2005) The clinical investigator as fiduciary: Discarding a misguided idea. The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics 33(3): 586–598.CrossRefGoogle Scholar
  43. Moynihan, R., Heath, I. and Henry, D. (2002) Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal 324(7342): 886–891.CrossRefGoogle Scholar
  44. Nguyen, V. (2010) The Republic of Therapy: Triage and Sovereignty in West Africa’s Time of AIDS. London: Duke University Press.CrossRefGoogle Scholar
  45. Petryna, A. (2005) Ethical variability: Drug development and globalizing clinical trials. American Ethnologist 32(2): 183–197.CrossRefGoogle Scholar
  46. Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press.CrossRefGoogle Scholar
  47. Petryna, A. (2015) Clinical trials offshored: On private sector science and public health. In: S. Sismondo and J.A. Green (eds.) The Pharmaceutical Studies Reader. West Sussex: Wiley-Blackwell, pp. 208–221.Google Scholar
  48. Pharmvestnik (2013) Vladimir Gurdus: There are conditions for innovation development in Russia. May 28.Google Scholar
  49. Schecter, K. (1992) Soviet socialized medicine and the right to health care in a changing Soviet Union. Human Rights Quarterly 14(2): 206–215.CrossRefGoogle Scholar
  50. Schroeder, D. and Gefenas, E. (2012) Realizing benefit sharing – The case of post-study obligations. Bioethics 26(6): 305–314.CrossRefGoogle Scholar
  51. Setouhy, M.E. et al (2004) Moral standards for research in developing countries. From “reasonable availability” to “fair benefits”. The Hastings Center Report 34(3): 17–27.CrossRefGoogle Scholar
  52. Star, S.L. (1989) The structure of ill-structured solutions: Boundary objects and distributed heterogeneous problem solving. In: L. Gasser and M. Huhns (eds.) Distributed Artificial Intelligence 2. San Mateo, CA: Morgan Kauffmann, pp. 37–54.CrossRefGoogle Scholar
  53. Star, S.L. (2010) This is not a boundary object: Reflections on the origin of a concept. Science, Technology, & Human Values 35(5): 601–617.CrossRefGoogle Scholar
  54. Star, S.L. and Griesemer, J. (1989) Institutional ecology, “translation” and boundary objects: Amateurs and professionals in Berkeley’s museum of vertebrate zoology, 1907–30. Social Studies of Science 19(3): 387–420.CrossRefGoogle Scholar
  55. Stefanov, I. (2007) Clinical trials come to Russia. International Clinical Trials (Fall): 43–50.Google Scholar
  56. Stefanov, I. (2008) Russian revolution. European Pharmaceutical Contractor (Spring): 14–18.Google Scholar
  57. Stefanov, I. and Tverdokhleb, P. (2008) Russia grows its CRO market. Applied Clinical Trials, 1 April.Google Scholar
  58. Sunder Rajan, K. (2010) The experimental machinery of global clinical trials: Case studies from India. In: A. Ong and N.N. Chen (eds.) Asian Biotech: Ethics and Communities of Fate. Durham: Duke University Press, pp. 55–80.CrossRefGoogle Scholar
  59. Timmermans, S. and McKay, T. (2009) Clinical trials as treatment option: Bioethics and health care disparities in substance dependency. Social Science & Medicine 69(12): 1784–1790.CrossRefGoogle Scholar
  60. Wadmann, S. (2014) Physician−industry collaboration: Conflicts of interest and the imputation of motive. Social Studies Of Science 44(4): 531–554.CrossRefGoogle Scholar
  61. Wadmann, S. and Hoeyer, K. (2014) Beyond the “therapeutic misconception”: Research, care and moral friction. BioSocieties 9(1): 3–23.CrossRefGoogle Scholar
  62. Williams, S., Martin, P. and Gabe, J. (2011) The pharmaceuticalisation of society? A framework for analysis. Sociolology of Health & Illness 33(5): 710–725.CrossRefGoogle Scholar
  63. Wolters, A., de Wert, G., van Schayck, O. and Horstman, K. (2014) Constructing a trial as a personal lifestyle project: Participants’ experiences in a clinical study for nicotine vaccination. Social Science & Medicine 104: 116–123.CrossRefGoogle Scholar
  64. Zingerman, B. (2013) Electronic medical record and principles of its organisation. IT in Health Care/Зингерман, Б. (2013) Электронная медицинская карта и принципы ее организации. ИТ в здравоохранении., accessed 1 February 2014.
  65. Zvonareva, O., Engel, N., Martsevich, S., de Wert, G. and Horstman, K. (2015) International clinical trials, cardiovascular disease and treatment options in the Russian Federation: Research and treatment in practice. Social Science and Medicine 128: 255–262.CrossRefGoogle Scholar

Copyright information

© Macmillan Publishers Ltd 2016

Authors and Affiliations

  • Olga Zvonareva
    • 1
    • 2
    Email author
  • Nora Engel
    • 1
  • Natalia Kutishenko
    • 3
  • Klasien Horstman
    • 1
  1. 1.Department of Health, Ethics and Society, Maastricht UniversityMaastrichtthe Netherlands
  2. 2.Policy Analysis and Studies of Technologies Centre, National Research Tomsk State UniversityTomskRussian Federation
  3. 3.Department of Preventive Pharmacotherapy, the National Research Center for Preventive MedicineMoscowRussian Federation

Personalised recommendations